Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris
NCT ID: NCT03198091
Last Updated: 2017-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2017-03-30
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial Scheme of Xinnaoning Capsule
NCT03914131
Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris
NCT04270279
Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary Syndrome
NCT03669991
To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina
NCT02623569
A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome
NCT03413410
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dun Ye Guan Xin Ning mono-therapy
Dun Ye Guan Xin Ning
Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dun Ye Guan Xin Ning
Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented stable angina pectoris.
3. During a period of time (more than 3 months), the duration, severity and the threshold of angina is relatively stable.
4. Patients with at least one of the following events: ① patients who have done PCI or CABG for more than half a year; ② coronary CTA angiography or coronary angiography showed at least one major coronary artery stenosis ≥ 50%. Symptom occurs at least once per month.
5. Medications remain stable within 1 month before the enrollment.
6. Patients have the ability to understand the study, and can cooperate with researchers to carry out the test.
7. Signed inform consent.
Exclusion Criteria
2. Patients with aortic stenosis, hypertrophic cardiomyopathy and other diseases leading to angina.
3. Patients have other heart disease, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, biliary heart disease, gastroesophageal reflux caused by chest pain.
4. Patients combined with severe cardiopulmonary insufficiency (NYHA grade III ord IV), pulmonary insufficiency graded reference COPD clinical severity of lung function grade III (FEV1 / FVC \<70%, 30% 1 / FVC% of predicted value \<50%) and grade IV), severe arrhythmia (eg. III degree atrioventricular block)
5. Patients combined with liver, kidney, hematopoietic system and other serious primary disease patients (TBil ≥ 1.5ULN, AST ≥ 2ULN, ALT ≥ 2ULN, serum creatinine ≥ 1.5ULN, Hb \<9mg/dL).
6. Patients with cognitive, intellectual, or mental disorders.
7. Those who can not take oral medication.
8. Allergy to any component of this product.
9. Patients received the trial medication within 28 days prior to the first treatment of this product.
10. Lactating or pregnant women.
11. Patients who are unwilling or unable to contraceptive in the reproductive period.
12. Poor medication compliance.
13. Other circumstances that the investigator considers unsuitable for inclusion.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Wanbang Pharmaceutical Marketing Co.,Ltd.
UNKNOWN
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yong Huo
Director of the Department of Cardiology and heart center of Peking University First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DY-SH-1601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.